West Pharmaceutical Lifts 2026 Outlook After 29% EPS Jump as GLP-1 Demand Accelerates
Updated
Updated · CNBC · Aug 5
West Pharmaceutical Lifts 2026 Outlook After 29% EPS Jump as GLP-1 Demand Accelerates
1 articles · Updated · CNBC · Aug 5
Summary
West Pharmaceutical said second-quarter adjusted EPS rose 29% year over year, prompting its second 2026 guidance increase after a rebound from the 2024 inventory slowdown.
GLP-1 therapies and biologics are driving the upswing: GLP-1 products made up 18% of second-quarter net sales, while biologics contributed 43% of revenue.
EU Annex 1 sterile-manufacturing rules are also boosting demand for West’s higher-margin components; the company said it now has nearly 800 related projects, up about 50% from a year earlier.
Michel Lagarde, a former Thermo Fisher executive, will take over as CEO on Aug. 31 as West expands partnerships and refocuses delivery systems for larger injectable volumes.
Shares have returned 46% over the past year and trade around 44 times earnings, reflecting investor bets that injectable drug growth and regulatory switching costs can sustain double-digit profit expansion.
With a new CEO taking charge, will hidden cybersecurity vulnerabilities derail this premium stock's massive growth fueled by the biologics boom?
How might a recent ransomware attack on this vital packaging supplier threaten the global supply chain for blockbuster GLP-1 weight-loss drugs?
Could the shift toward oral alternatives for weight-loss therapies eventually dismantle the impenetrable regulatory moat protecting this injectable packaging giant?